BioXcel Therapeutics, Inc. 10-K filing
Filed 2026-03-27 · Report date 2025-12-31 · 2025 FY
Filing metadata
- Accession number
- 0001104659-26-036214
- Form type
- 10-K
- CIK
- 0001720893
- Primary document
- https://www.sec.gov/Archives/edgar/data/1720893/000110465926036214/btai-20251231x10k.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for BioXcel Therapeutics, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $642,000 | - | - |
| Cost Of Revenue | $164,000 | - | - |
| Operating Income | $-50.5M | - | - |
| Net Income | $-69.9M | - | - |
| Eps Basic | -5.73 | - | - |
| Eps Diluted | -5.73 | - | - |
| Cash And Equivalents | $28.4M | - | - |
| Total Assets | $44.9M | - | - |
| Total Liabilities | $140.4M | - | - |
| Shareholders Equity | $-95.5M | - | - |
| Operating Cash Flow | $-57.6M | - | - |
| Capital Expenditures | $0 | - | - |